Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $97,853.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 7,988 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $12.25, for a total value of $97,853.00. Following the sale, the chief financial officer directly owned 137,987 shares in the company, valued at $1,690,340.75. This represents a 5.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Entrada Therapeutics Trading Up 8.3%

Shares of NASDAQ TRDA opened at $12.58 on Monday. The stock has a market cap of $481.56 million, a P/E ratio of -3.64 and a beta of -0.12. The business’s fifty day simple moving average is $11.05 and its 200-day simple moving average is $8.73. Entrada Therapeutics, Inc. has a 12-month low of $4.93 and a 12-month high of $12.93.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.38. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.The firm had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $7.41 million. On average, equities analysts forecast that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. Oppenheimer began coverage on shares of Entrada Therapeutics in a report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. Finally, Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Entrada Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

More Entrada Therapeutics News

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained a $20.00 price target on TRDA, which signals meaningful upside from current levels and likely supported buying interest. HC Wainwright note
• Positive Sentiment: HC Wainwright nudged its Q1 2026 EPS estimate to a smaller loss (from ($1.20) to ($1.12)), a modest improvement that can be read as slightly better near‑term expectations for operating performance. HC Wainwright note
• Neutral Sentiment: Short‑interest data reported a jump claim but shows 0 shares short (short‑interest ratio 0.0 days); this appears to be a data anomaly. If accurate, near‑zero reported short interest reduces downward short‑pressure, but the feed’s inconsistency makes this point uncertain. Short interest report
• Negative Sentiment: HC Wainwright cut several near‑term EPS forecasts (Q2–Q4 2026 and FY2026 lowered; FY2026 moved to ($4.49) from ($4.21)) and trimmed multiple 2026/2027 quarterly EPS views, signaling larger expected losses in the near term. Deteriorating near‑term profitability expectations could pressure the stock if operational or cash‑burn concerns persist. HC Wainwright note

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TRDA. Russell Investments Group Ltd. lifted its stake in Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares during the last quarter. State of Wyoming increased its stake in Entrada Therapeutics by 130.9% in the second quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after purchasing an additional 4,295 shares during the last quarter. AXQ Capital LP purchased a new position in Entrada Therapeutics in the third quarter valued at approximately $67,000. Occudo Quantitative Strategies LP acquired a new stake in Entrada Therapeutics during the second quarter worth approximately $68,000. Finally, Inscription Capital LLC acquired a new stake in Entrada Therapeutics during the third quarter worth approximately $69,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.